Does Biktarvy Cause Weight Gain?
Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide), an integrase inhibitor-based HIV regimen, is associated with weight gain in some patients, though less than older regimens like efavirenz or older integrase inhibitors. Clinical trials showed average weight increases of 1-2 kg over 48-96 weeks, with higher rates in women, Black patients, and those switching from other antiretrovirals.[1][2] Post-marketing data from real-world studies report median gains of 2-5 kg after 1-2 years, affecting 10-20% of users noticeably.[3]
How Common Is Weight Gain on Biktarvy?
In phase 3 trials (e.g., GS-US-380-4030), 15-25% of treatment-naive patients gained ≥5% body weight by week 48, compared to 10% on comparators like dolutegravir. Switching studies (e.g., from boosted darunavir) saw 20-30% with ≥5% gain. Long-term data up to 3 years indicate continued modest increases, plateauing for many.[1][4] FDA labeling notes weight gain as a potential effect, without specifying causality.[5]
Why Does Biktarvy Lead to Weight Gain?
Integrase inhibitors like bictegrivir may disrupt appetite regulation or fat metabolism via central nervous system effects or improved viral control restoring normal metabolism. Tenofovir alafenamide (TAF) contributes less nephrotoxicity than tenofovir disoproxil fumarate (TDF), potentially allowing better nutrient retention. Risk factors include baseline BMI <25, female sex, longer treatment duration, and prior stavudine use.[2][6]
How Does Biktarvy Compare to Other HIV Drugs for Weight Gain?
| Drug/Regimen | Avg. Weight Gain (1-2 yrs) | % with ≥5% Gain |
|--------------|-----------------------------|-----------------|
| Biktarvy | 1-3 kg | 15-25% |
| Tivicay (DTG) | 2-4 kg | 20-30% |
| Descovy-based | 1-2 kg | 10-20% |
| Efavirenz | 0-1 kg (or loss) | <10% |
| Older NRTIs (e.g., TDF/FTC + EFV) | Minimal or loss | <5% |
Biktarvy causes less gain than dolutegravir + TAF/FTC but more than NNRTI or PI-based options. Recent switches to Biktarvy from tenofovir disoproxil show accelerated gain.[3][4]
What Do Patients Report About Weight Gain?
User forums (e.g., Reddit, TheBody) and surveys note 5-15 lb gains in 6-12 months, often abdominal fat redistribution. Some reverse it with diet/exercise; others switch to lower-risk regimens like lenacapavir combos. No strong link to diabetes, but monitor lipids.[7]
Managing or Avoiding Weight Gain on Biktarvy
Lifestyle changes (calorie control, resistance training) mitigate 50-70% of gains per studies. Alternatives: Doravirine or TDF-based regimens for lower risk. Consult providers before switching—virologic failure risks apply. No dedicated reversal trials exist.[6][8]
[1] Clinical Trials of Biktarvy (JAIDS, 2020)
[2] NEJM: Bictegravir Phase 3 Data
[3] Lancet HIV: Real-World Weight Changes
[4] DHHS HIV Guidelines: Weight Gain Section
[5] Biktarvy FDA Label (2023)
[6] IDSA: HIV Weight Gain Guidance
[7] AIDSmap Patient Reports
[8] HIV.gov: Management Strategies